Señales en vivo de EGTX.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:29):

Stats
Volumen de hoy	568 552
Volumen promedio	344 445
Capitalización de mercado	1.68B
EPS	SEK0 ( 2024-02-21 )
Próxima fecha de ganancias	( SEK-0.310 ) 2024-05-02
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-4.42
ATR14	SEK0.0250 (0.43%)

Volumen Correlación

Largo: 0.28 (neutral)

Corto: 0.60 (weak)

Signal:(59.783) Neutral

Egetis Therapeutics AB Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Egetis Therapeutics AB Correlación - Moneda/Commodity

-0.56
( weak negative )

-0.44
( neutral )

0.00
( neutral )

-0.58
( weak negative )

0.02
( neutral )

0.45
( neutral )

Egetis Therapeutics AB Finanzas

Annual	2023
Ingresos:	SEK57.60M
Beneficio Bruto:	SEK-126.80M (-220.14 %)
EPS:	SEK-1.270

FY	2023
Ingresos:	SEK57.60M
Beneficio Bruto:	SEK-126.80M (-220.14 %)
EPS:	SEK-1.270

FY	2023
Ingresos:	SEK0
Beneficio Bruto:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
Ingresos:	SEK22.50M
Beneficio Bruto:	SEK-120.10M (-533.78 %)
EPS:	SEK-0.980

Financial Reports:

No articles found.

Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Actualizaciones en tiempo real para Egetis Therapeutics AB [EGTX.ST]

Upcoming Earnings Alert